A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

LONDON, Feb 26 (Reuters) - Britain's Ark Therapeutics said on Thursday it had filed a patent application for a new genetic technique that represents an advance in so-called RNA interference technology ...

Ionis is a leader in RNA-based therapies, and its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The firm's antisense ...

Decaffeinated coffee is increasingly popular because it lacks the stimulatory effects of caffeine that can trigger palpitations, increased blood pressure, and insomnia. Currently, coffee is ...